Drug Approval | April 26, 2022
Corbevax gets DCGI nod for Emergency Use in 5-12 years
The approval comes soon after Corbevax was given the nod for 12-15-year group
The approval comes soon after Corbevax was given the nod for 12-15-year group
Covaxin was earlier approved for children 12-18 years of age
The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
This is the first major brand refresh of CanSinoBIO since its inception in 2009
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Continuation of pediatric expansion in adolescents of PREVENT-19 Phase 3 trial will evaluate safety and immunogenicity of a booster dose
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
Pre-exposure prevention trial reduced risk of symptomatic Covid-19, with no severe disease or Covid-19-related deaths in the Evusheld group
The MicroGEM Saliva test is the first point of care PCR saliva test for Covid-19 delivering results in minutes
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
Subscribe To Our Newsletter & Stay Updated
